Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Vistagen Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, Stifel, Nicolaus & Company, Incorporated, and William Blair & Company, L.L.C. valued at combined offering price for each share of Common Stock, accompanying T1 Warrant and accompanying T2 (effective 2023-10-02).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Jefferies LLC, Stifel, Nicolaus & Company, Incorporated, and William Blair & Company, L.L.C.
- Value
- combined offering price for each share of Common Stock, accompanying T1 Warrant and accompanying T2
- Effective
- 2023-10-02
Exact text from the filing
On October 2, 2023, Vistagen Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Stifel, Nicolaus & Company, Incorporated, and William Blair & Company, L.L.C., as the representatives of the underwriters listed on Schedule A attached thereto (the “Underwriters”), in connection with the underwritten offering, issuance and sale by the Company of 15,010,810 shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), pre-funded warrants to purchase up to 3,577,240 shares of Common Stock (the “Pre-Funded Warrants”), warrants to purchase up to 9,294,022 shares of Common Stock (or pre-funded warrants to purchase up to 9,294,022 shares of Common Stock in lieu thereof) (the “T1 Warrants”) and warrants to purchase 11,265,086 shares of Common Stock (or pre-funded warrants to purchase up to 11,265,086 shares of Common Stock in lieu thereof) (the “T2 Warrants”).
View on SEC.gov